IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Anemia, Refractory, With Excess of Blasts Intervention:   Drug: IGF/MTX Sponsor:   IGF Oncology, LLC Not yet recruiting - verified May 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials